May 23, 2024

For people who have been through menopause and have taken menopausal hormone therapy, conjugated equine estrogen (CEE) taken alone may increase the risk of developing and dying from ovarian cancer, while CEE combined with medroxyprogesterone acetate (MPA) does not increase this risk and may reduce the risk of developing uterine cancer. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4 in Chicago, Illinois.

May 23, 2024

An artificial intelligence-based patient navigator tool demonstrated improved potential in helping to overcome patient attrition that can lead to colon cancer disparities, nearly doubling the rate of completed colonoscopies for people who did not show for their initial appointment. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4 in Chicago, Illinois. 

May 23, 2024

Results from a new study suggest that the human papillomavirus (HPV) vaccine is effective in preventing the development of several types of cancers caused by HPV, most particularly head and neck cancer in males. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4 in Chicago, Illinois. 

May 23, 2024

A new study found that most survivors of stage 0 through stage III breast cancer who try to conceive after completing treatment are able to become pregnant and have a live birth. The research will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4 in Chicago, Illinois. 

May 15, 2024

A new study published today in the Journal of Clinical Oncology provides compelling evidence that genital talc use is associated with an increased risk of ovarian cancer. This extensive analysis, part of the Sister Study cohort, revisits the association between intimate care products and cancer, incorporating rigorous adjustments for biases that might have affected earlier studies. 

May 15, 2024

A new study published in the Journal of Clinical Oncology shows encouraging results for the combination therapy of pertuzumab and trastuzumab in treating advanced biliary tract cancer (BTC) with ERBB2/3 alterations. The incidence and mortality rates of BTC have risen significantly in recent years, with a 5-year survival rate of only 2% for patients with metastatic disease. 

May 6, 2024

The American Society of Clinical Oncology (ASCO) announced four additional medical schools have been selected to participate in the Society’s Oncology Summer Internship (OSI) Program.

April 29, 2024

Patients with KRASG12C mutated-non-small cell lung cancer (NSCLC) who were treated with glecirasib, a KRASG12C-inhibitor, experienced promising outcomes according to new findings that will be presented in the upcoming April 2024 session of the American Society of Clinical Oncology (ASCO) Plenary Series.

April 25, 2024

The American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) are calling on manufacturers of diagnostics and therapeutics to adopt therapeutic group labeling to improve access to effective modern therapies for patients,

April 24, 2024

The global oncology community will gather in Chicago to share and discuss the latest clinical cancer research impacting patient care at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Treatment advances involving targeted therapies, immunotherapy, and new uses of technology, as well as research on improving patient quality of life and outcomes are among the topics that will be highlighted in the meeting’s official Press Program.  

April 17, 2024

Cancer doctors from across the U.S. are lending their voices to a new advocacy campaign to end drug shortages. Led by the Association for Clinical Oncology (ASCO), nearly 500 oncology professionals have signed an open letter to Congress and the administration highlighting the severe impact of drug shortages on cancer care and urging swift action from lawmakers.

March 28, 2024

Today the Department of Health and Human Services (HHS), Department of Labor and the Treasury Department finalized a rule regulating the availability of short-term limited duration insurance (STLDI) plans. The rule would restrict the availability of these plans to no more than four months.

March 22, 2024

Congress is expected to vote on a spending package March 22 that will fund the federal government, including the National Institutes of Health (NIH) and National Cancer Institute (NCI), through September 30— the end of the 2024 Fiscal Year.

March 14, 2024

A new ASCO policy statement is emphasizing the urgent need for global equity in clinical trials. The statement, which published March 14, 2024, in JCO Global Oncology, explains how global equity can be advanced by diversifying trial representation, increasing access to resources, and strengthening research capacity on a global scale.

March 7, 2024

The Association for Clinical Oncology (ASCO) is calling on President Biden to continue to prioritize access to high-quality, equitable cancer care in his State of the Union address. 

Pages